Cardiomyopathy due to anthracyclines
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.
On this page
The FDA has approved this product to be used in this manner.
|Cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative dose of 300mg/m2.|
|More Information about this product||
Drug Information Portal
Medline Plus Health Information